In COVID-19 clinical update #80, Daniel Griffin reviews infections in children, masking, testing to limit transmission, high barrier for monoclonal antibody escape, are boosters needed, use of steroids, grants for long COVID, and how the pandemic unfolds in Africa.
In COVID-19 clinical update #79, Daniel Griffin discusses clinical management guidelines, ER visits and hospitalization among children, infection and vaccine induced seroprevalence in the US, antibodies in Kenyan blood donors, infections after vaccination, anticoagulation for thromboprophylaxis, baracitinib efficacy, long-term symptoms in adults, and sustained symptoms after severe disease.
In COVID-19 clinical update #78, Daniel Griffin covers ivermectin, convalescent plasma, disease in pregnant women, children and COVID, delta outbreak in an elementary school, validation of at-home antigen test, shedding in infected vaccinated people, mRNA vaccine antibody responses compared, AZD7442, fluvoxamine, one year outcomes in hospitalized patients, and post-vaccination disease.
In COVID-19 clinical update #76, Daniel Griffin covers association of age and pediatric household transmission, rapid antigen testing in remote communities, shedding of infectious virus in vaccinated individuals, FDA amendment of mRNA vaccine EUA to allow a third dose, new vaccine mandate for NY state, full vaccination suppresses selection of variants, effectiveness of mRNA vaccines in nursing homes, sustained effectiveness of mRNA vaccines against hospitalization, and no benefit from early convalescent serum in high-risk outpatients.
In COVID-19 clinical update #75, Daniel Griffin reviews vaccine effectiveness against transmission, modeling effectiveness of daily antigen tests, updated CDC guidance for fully vaccinated, risk of infection with time after mRNA vaccination, reduced risk of infection after vaccination, therapeutic anticoagulants in critically ill patients, and 6 month outcomes in hospitalized patients.
In COVID-19 clinical update #74, Daniel Griffin covers infections in vaccinated individuals, expansion of Regeneron monoclonal antibody cocktail for prophylaxis, neutralization of variants by antibodies produced by infection or vaccination, longer hospital stays associated with remdesivir treatment, and post-acute sequelae of infection and impact on quality of life 1-6 months after illness.
In COVID-19 clinical update #73, Daniel Griffin reviews updated mask guidance from CDC, infections in public school district employees, effectiveness of vaccines against delta variant, antibody response after third vaccine dose in kidney transplant recipients, protection afforded by mRNA vaccines fully vaccinated people with and without prior infections, correlates of protection in nonhuman primates, lack of effectiveness of doxycycline, neurological manifestations of COVID-19, and infection in vaccinated health care workers.
In COVID-19 clinical update #72, Daniel Griffin covers long term symptoms in children, outcomes for MIS-C, recent guidance from the American Academy of Pediatrics, a large well traced outbreak of delta variant, low dose mRNA vaccination generates durable T cell memory and antibodies, protective immunity in recovered patients, assessment of BinaxNOW, no effect of oral azithromycin, post-discharge symptoms in Nigeria, and therapeutics for low and middle income countries.
In COVID-19 clinical update #67, Daniel Griffin reviews antibodies to the virus early in the US, serology testing of blood donations, MIS-C in children under 21, myocarditis in competitive athletes, ER visits for suspected suicide attempts, delta variant in Scotland, Novavax vaccine phase 3 results, vaccine coverage in pregnant women, early monoclonal administration reduces hospitalization and mortality, casirivimab and imdevimab recovery trial results, and CDC guidance on postacute sequelae.
In COVID-19 clinical update #66, Daniel Griffin covers treatment guidelines from IDSA, hospitalization of adolescents, estimating epidemiological dynamics from viral load distributions, incidence of infection according to baseline antibody status, assessment of reinfection in Italy, need for vaccination in previously infected individuals, assessment of protection against reinfection, antimicrobial use in hospitalized patients, effect of single dose ivermectin, and a trial of aspirin in hospitalized patients.